{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:36:40Z","timestamp":1792103800135,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-25816-0","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T03:04:57Z","timestamp":1765767897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and clinical characteristics of concurrent chronic hepatitis B and fatty liver disease in China: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Jiayi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengnan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luojia","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"25816_CR1","first-page":"101193","volume":"51","author":"Z Hui","year":"2024","unstructured":"Hui Z, Yu W, Fuzhen W, et al. New progress in HBV control and the cascade of health care for people living with HBV in china: evidence from the fourth National serological survey, 2020. Lancet Reg Health West Pac. 2024;51:101193.","journal-title":"Lancet Reg Health West Pac"},{"issue":"44","key":"25816_CR2","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.3748\/wjg.v24.i44.4959","volume":"24","author":"Y Waheed","year":"2018","unstructured":"Waheed Y, Siddiq M, Jamil Z, Najmi MH. Hepatitis elimination by 2030: progress and challenges. World J Gastroenterol. 2018;24(44):4959\u201361.","journal-title":"World J Gastroenterol"},{"key":"25816_CR3","unstructured":"Global Hepatitis Report. Geneva: World Health Organization. 2017. https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"issue":"2","key":"25816_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","volume":"224","author":"J Li","year":"2021","unstructured":"Li J, Yang HI, Yeh ML, et al. Association between fatty liver and Cirrhosis, hepatocellular Carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis. 2021;224(2):294\u2013302.","journal-title":"J Infect Dis"},{"issue":"5","key":"25816_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","volume":"17","author":"S Cheemerla","year":"2021","unstructured":"Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken). 2021;17(5):365\u201370.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"3","key":"25816_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/liv.14369","volume":"40","author":"J Zhang","year":"2020","unstructured":"Zhang J, Lin S, Jiang D, et al. Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors? Liver Int. 2020;40(3):496\u2013508.","journal-title":"Liver Int"},{"issue":"6","key":"25816_CR7","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","volume":"55","author":"E Amini-Salehi","year":"2024","unstructured":"Amini-Salehi E, Letafatkar N, Norouzi N, et al. Global prevalence of nonalcoholic fatty liver disease: an updated review Meta-Analysis comprising a population of 78 million from 38 countries. Arch Med Res. 2024;55(6):103043.","journal-title":"Arch Med Res"},{"issue":"2","key":"25816_CR8","doi-asserted-by":"publisher","first-page":"e98531","DOI":"10.5812\/hepatmon.98531","volume":"20","author":"N Motamed","year":"2020","unstructured":"Motamed N, Khoonsari M, Panahi M, Rezaie N, Maadi M, et al. The incidence and risk factors of Non-Alcoholic fatty liver disease: A cohort study from Iran. Hepat Mon. 2020;20(2):e98531.","journal-title":"Hepat Mon"},{"key":"25816_CR9","doi-asserted-by":"crossref","unstructured":"Huh Y, Cho YJ, Nam GE. Recent epidemiology and risk factors of nonalcoholic fatty liver disease. JOMES. 2022;31:17\u201327.","DOI":"10.7570\/jomes22021"},{"issue":"4","key":"25816_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1053\/j.gastro.2023.05.053","volume":"165","author":"S Man","year":"2023","unstructured":"Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various High-Risk populations: A nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165(4):1025\u201340.","journal-title":"Gastroenterology"},{"issue":"2","key":"25816_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12072-020-10023-3","volume":"14","author":"Y Wu","year":"2020","unstructured":"Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int. 2020;14(2):259\u201369.","journal-title":"Hepatol Int"},{"issue":"4","key":"25816_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and Meta-Analysis. Hepatology. 2019;70(4):1119\u201333.","journal-title":"Hepatology"},{"issue":"1","key":"25816_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/jgh.12428","volume":"29","author":"Z Li","year":"2014","unstructured":"Li Z, Xue J, Chen P, Chen L, Yan S, Liu L. Prevalence of nonalcoholic fatty liver disease in Mainland of china: a meta-analysis of published studies. J Gastroenterol Hepatol. 2014;29(1):42\u201351.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"25816_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","volume":"5","author":"The global","year":"2020","unstructured":"The global. regional, and National burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245\u201366.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"25816_CR15","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","volume":"18","author":"AM Moon","year":"2020","unstructured":"Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650\u201366.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"25816_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"25816_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","volume":"17","author":"SC Huang","year":"2023","unstructured":"Huang SC, Su TH, Tseng TC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17(5):1139\u201349.","journal-title":"Hepatol Int"},{"key":"25816_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2147\/JHC.S355540","volume":"9","author":"RC Hsueh","year":"2022","unstructured":"Hsueh RC, Wu WJ, Lin CL, et al. Impact of PNPLA3 p.I148M and hepatic steatosis on Long-Term outcomes for hepatocellular carcinoma and HBsAg seroclearance in chronic hepatitis B. J Hepatocell Carcinoma. 2022;9:301\u201313.","journal-title":"J Hepatocell Carcinoma"},{"issue":"4","key":"25816_CR19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s12072-021-10218-2","volume":"15","author":"LY Mak","year":"2021","unstructured":"Mak LY, Hui RW, Fung J, et al. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int. 2021;15(4):901\u201311.","journal-title":"Hepatol Int"},{"key":"25816_CR20","doi-asserted-by":"crossref","unstructured":"Hanif H, Khan MM, Ali MJ, et al. A new endemic of concomitant nonalcoholic fatty liver disease and chronic hepatitis B. Microorganisms. 2020;8(10).","DOI":"10.3390\/microorganisms8101526"},{"issue":"10","key":"25816_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jvh.13872","volume":"30","author":"R Zhou","year":"2023","unstructured":"Zhou R, Yang L, Zhang B, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in asia: A systematic review and meta-analysis. J Viral Hepat. 2023;30(10):793\u2013802.","journal-title":"J Viral Hepat"},{"issue":"2","key":"25816_CR22","doi-asserted-by":"publisher","first-page":"101483","DOI":"10.1016\/j.clinre.2020.06.009","volume":"45","author":"S Lin","year":"2021","unstructured":"Lin S, Wang M, Liu Y, et al. Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease. Clin Res Hepatol Gastroenterol. 2021;45(2):101483.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"25816_CR23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41598-020-80709-z","volume":"11","author":"DD Lv","year":"2021","unstructured":"Lv DD, Wang YJ, Wang ML, et al. Effect of Silibinin capsules combined with lifestyle modification on hepatic steatosis in patients with chronic hepatitis B. Sci Rep. 2021;11(1):655.","journal-title":"Sci Rep"},{"issue":"9","key":"25816_CR24","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1440-1746.2011.06801.x","volume":"26","author":"MV Machado","year":"2011","unstructured":"Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26(9):1361\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"25816_CR25","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/jmv.25621","volume":"92","author":"J Huang","year":"2020","unstructured":"Huang J, Jing M, Wang C, et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: A population-based study. J Med Virol. 2020;92(8):1191\u20137.","journal-title":"J Med Virol"},{"issue":"3","key":"25816_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","volume":"56","author":"VW Wong","year":"2012","unstructured":"Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56(3):533\u201340.","journal-title":"J Hepatol"},{"issue":"26","key":"25816_CR27","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.3748\/wjg.v27.i26.3971","volume":"27","author":"YW Shi","year":"2021","unstructured":"Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: current evidence and opinion. World J Gastroenterol. 2021;27(26):3971\u201383.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"25816_CR28","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/hep.28917","volume":"65","author":"EJ Joo","year":"2017","unstructured":"Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology. 2017;65(3):828\u201335.","journal-title":"Hepatology"},{"issue":"63","key":"25816_CR29","doi-asserted-by":"publisher","first-page":"107295","DOI":"10.18632\/oncotarget.22364","volume":"8","author":"J Xiong","year":"2017","unstructured":"Xiong J, Zhang H, Wang Y, et al. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis. Oncotarget. 2017;8(63):107295\u2013302.","journal-title":"Oncotarget"},{"key":"25816_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-med-090514-013832","volume":"67","author":"A Marengo","year":"2016","unstructured":"Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with Obesity, fatty Liver, and cirrhosis. Annu Rev Med. 2016;67:103\u201317.","journal-title":"Annu Rev Med"},{"issue":"8","key":"25816_CR31","doi-asserted-by":"publisher","first-page":"e72049","DOI":"10.1371\/journal.pone.0072049","volume":"8","author":"YL Cheng","year":"2013","unstructured":"Cheng YL, Wang YJ, Kao WY, et al. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS ONE. 2013;8(8):e72049.","journal-title":"PLoS ONE"},{"issue":"3","key":"25816_CR32","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082\u201390.","journal-title":"Hepatology"},{"issue":"6","key":"25816_CR33","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled Attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717\u201330.","journal-title":"Gastroenterology"},{"issue":"3\u20134","key":"25816_CR34","first-page":"218","volume":"124","author":"YC Lai","year":"2013","unstructured":"Lai YC, Cheng BC, Hwang JC, et al. Association of fatty liver disease with nonfatal cardiovascular events in patients undergoing maintenance Hemodialysis. Nephron Clin Pract. 2013;124(3\u20134):218\u201323.","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"25816_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000360270","volume":"37","author":"I Mikolasevic","year":"2014","unstructured":"Mikolasevic I, Orlic L, Milic S, Zaputovic L, Lukenda V, Racki S. Non-alcoholic fatty liver disease proven by transient elastography in Hemodialysis patients: is it a new risk factor for adverse cardiovascular events? Blood Purif. 2014;37(4):259\u201365.","journal-title":"Blood Purif"},{"issue":"7","key":"25816_CR36","first-page":"431","volume":"91","author":"A Ben Slama Trabelsi","year":"2013","unstructured":"Ben Slama Trabelsi A, Ksiaa M, Souguir A, Issaoui D, Sriha B, Ajmi S. [Hepatic steatosis in chronic hepatitis B: prevalence, risk factors, and impact on fibrosis and therapeutic response]. Tunis Med. 2013;91(7):431\u20134.","journal-title":"Tunis Med"},{"issue":"4","key":"25816_CR37","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801.","journal-title":"J Hepatol"},{"key":"25816_CR38","doi-asserted-by":"crossref","unstructured":"Hu Y, Tang W, Liu Y, et al. Temporal relationship between hepatic steatosis and blood pressure elevation and the mediation effect in the development of cardiovascular disease. Hypertens Res. 2024.","DOI":"10.1038\/s41440-024-01708-5"},{"issue":"1","key":"25816_CR39","doi-asserted-by":"publisher","first-page":"10185","DOI":"10.1038\/s41598-023-37274-y","volume":"13","author":"X Lyu","year":"2023","unstructured":"Lyu X, Du Y, Liu G, et al. Prevalence and influencing factors of hyperuricemia in middle-aged and older adults in the Yao minority area of china: a cross-sectional study. Sci Rep. 2023;13(1):10185.","journal-title":"Sci Rep"},{"issue":"1","key":"25816_CR40","doi-asserted-by":"publisher","first-page":"E62","DOI":"10.1152\/ajpendo.00001.2023","volume":"325","author":"J Liu","year":"2023","unstructured":"Liu J, Wang C, Wang YT, et al. Hyperuricemia as an independent risk factor for metabolic dysfunction-associated fatty liver disease in Nonobese patients without type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2023;325(1):E62\u201371.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10019","key":"25816_CR41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390.","journal-title":"Lancet"},{"issue":"8","key":"25816_CR42","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41(8):1801\u20138.","journal-title":"Diabetes Care"},{"issue":"5","key":"25816_CR43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamainternmed.2025.0115","volume":"185","author":"J Choi","year":"2025","unstructured":"Choi J, Nguyen VH, Przybyszewski E, et al. Statin use and risk of hepatocellular carcinoma and liver fibrosis in chronic liver disease. JAMA Intern Med. 2025;185(5):522\u201330.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"25816_CR44","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.metabol.2012.07.022","volume":"62","author":"PT Liu","year":"2013","unstructured":"Liu PT, Hwang AC, Chen JD. Combined effects of hepatitis B virus infection and elevated Alanine aminotransferase levels on dyslipidemia. Metabolism. 2013;62(2):220\u20135.","journal-title":"Metabolism"},{"issue":"11","key":"25816_CR45","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/j.1440-1746.2010.06300.x","volume":"25","author":"JY Chen","year":"2010","unstructured":"Chen JY, Wang JH, Lin CY, et al. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B and C strains independently. J Gastroenterol Hepatol. 2010;25(11):1763\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"47","key":"25816_CR46","doi-asserted-by":"publisher","first-page":"17932","DOI":"10.3748\/wjg.v20.i47.17932","volume":"20","author":"RN Feng","year":"2014","unstructured":"Feng RN, Du SS, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20(47):17932\u201340.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"25816_CR47","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1128\/JVI.02604-15","volume":"90","author":"YL Wu","year":"2016","unstructured":"Wu YL, Peng XE, Zhu YB, Yan XL, Chen WN, Lin X, Hepatitis B, Virus X. Protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein. J Virol. 2016;90(4):1729\u201340.","journal-title":"J Virol"},{"issue":"5","key":"25816_CR48","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1053\/j.gastro.2007.03.039","volume":"132","author":"KH Kim","year":"2007","unstructured":"Kim KH, Shin HJ, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology. 2007;132(5):1955\u201367.","journal-title":"Gastroenterology"},{"issue":"1","key":"25816_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejim.2014.12.001","volume":"26","author":"R Pais","year":"2015","unstructured":"Pais R, Rusu E, Zilisteanu D, et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. Eur J Intern Med. 2015;26(1):30\u20136.","journal-title":"Eur J Intern Med"},{"issue":"7","key":"25816_CR50","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3390\/biom15070956","volume":"15","author":"I Kiss","year":"2025","unstructured":"Kiss I, Neuwert N, Oberle R, Hengstschl\u00e4ger M, Osmanagic-Myers S, Stangl H. Hepatic lipoprotein metabolism: current and future in vitro Cell-Based systems. Biomolecules. 2025;15(7):956.","journal-title":"Biomolecules"},{"issue":"7","key":"25816_CR51","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1001\/archinte.1997.00440280120012","volume":"157","author":"C Cicognani","year":"1997","unstructured":"Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med. 1997;157(7):792\u20136.","journal-title":"Arch Intern Med"},{"issue":"1","key":"25816_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","volume":"1","author":"N Peleg","year":"2019","unstructured":"Peleg N, Issachar A, Sneh Arbib O, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep. 2019;1(1):9\u201316.","journal-title":"JHEP Rep"},{"issue":"1","key":"25816_CR53","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1):101133.","journal-title":"Ann Hepatol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-25816-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:22:28Z","timestamp":1768922548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-25816-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["25816"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-25816-0","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This was a systematic review and meta-analysis thus ethical approval and consent to participate were not required. The conduct and reporting of this research were in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}